TRIM7

HAMILTON, Ontario, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Exerkine Corporation (the "Company" or "Exerkine") is pleased to announce that it has successfully transitioned from its pre-revenue development phase into commercial operations. Importantly, Exerkine’s R&D pipeline is maturing and generating patented nutrition-based therapies that are supported by strong clinical results. These therapies are particularly impactful at a time when North American obesity rates and age-related disorders are at pandemic levels. The biggest threats to North American health are obesity and age-related disorders (i.e. muscle loss, cardiovascular disease, type 2 diabetes, dementia). Current nutritional strategies to combat these health issues have been shown to be ineffective in the long term. Exerkine is poised to change this paradigm through proprietary products that are built and backed by science. Founded by Dr. Mark Tarnopolsky, and in partnership with McMaster University, Exerkine is a Canadian nutritional supplements company built upon decades of research. Utilizing advances in mitochondrial sciences, exercise physiology, and nutrition, Exerkine leverages pharmaceutical-industry R&D standards to create novel nutrition-based products. This rigorous development pipeline sets Exerkine apart by ensuring that its nutritional products are supported by high quality preclinical and clinical research, supported by proven health claims, and meet safety and regulatory standards, which, when combined, deliver superior products to consumers. Exerkine is led by internationally renowned physician-scientist, Dr. Mark Tarnopolsky, PhD, MD, FRCP(C). As the founder, CEO and CSO of Exerkine, Dr. Tarnopolsky is applying his clinical and scientific expertise to lead Exerkine’s commercial and research development. Having successfully co-founded and acted as CSO for Life Science Nutritionals, he has expanded his business acumen as the co-founder and Vice President of Business Development for Systemic Therapeutics, and CSO for SoftTabs. Additionally, he has forged a career studying the impact of exercise and nutritional therapies in the treatment of aging-acquired and genetic disorders. He holds an endowed chair in, and is division head of, Neuromuscular and Neurometabolic Diseases Clinic at the McMaster University Children’s Hospital and is an advisor on numerous medical advisory boards. Dr. Tarnopolsky’s extensive research and medical knowledge is exemplified by over 500 published scientific and medical manuscripts (h index = 141) and has received high-profile attention from media outlets such as CBC News, ABC News, Wall Street Journal, New York Times, and Time magazine. “Exerkine is at the forefront of a new phase in its development. Having been supported by McMaster University as a start-up company, we are looking to expand our operations by fostering new partnerships, expanding our research program, and by bring our game-changing evidence-backed products to market.” Dr. Tarnopolsky continued to say “we are thrilled to see what the future holds for Exerkine - a company that’s truly built and backed by science.” Core to its R&D strategy, Exerkine is actively engaged in developing a diverse patent portfolio. The corporation’s initial filing outlined the novel use of interleukin-15, a cytokine known to be involved in a variety of biological pathways, to promote mitochondrial biogenesis and drive improvements in skin health. This patent has been awarded in both Canada (CA2917944C) and the United States (US10064919B2) and has garnered attention from companies in the skincare and beauty industry. Exerkine has since gone on to develop and submit over two dozen patent applications and the company will be making several exciting announcements as its portfolio matures. As part of its evolving commercial strategy, Exerkine launched its nutrition subdivision, StayAbove Nutrition. Through StayAbove Nutrition, Exerkine is marketing several novel nutrition-based products to the consumer. These products are designed to target a health disorder from multiple pathways to yield a combined therapeutic benefit. Clinical results have shown that these products not only provide preventative options to combat obesity and aging-related disorders, but also show treatment options for those already suffering from these conditions. Exerkine is excited to present its two flagship products: Muscle 5 (Muscle Enhancement Supplement) and Trim 7 (Weight Management Supplement) under StayAbove Nutrition. Muscle 5 is a nutritional supplement containing 5 carefully selected ingredients shown to enhance muscle mass and strength in younger and older adults. Unlike single ingredient protein powders, Muscle 5’s patented design is proven to build muscle and strength, and has been shown to impact blood cholesterol levels, as well as cognition (Nilsson et al, 2020; Bell et al, 2017; Bell et al, 2019). Trim 7 is a weight management supplement containing 7 specific ingredients shown to reduce fat mass but preserve lean mass. Trim7’s patented design focuses on the mitochondria, the cell’s powerhouse, to drive weight loss by turning on the body’s natural fat burning pathways. A significant amount of research and development has already been done on this product, including pre-clinical (Nederveen et al, 2021) work, and the company will be announcing its clinical trial results in a press release shortly. About ExerkineExerkine Corporation is a nutra-pharmaceutical company that is developing a new class of therapies to treat obesity and age-related disorders . Advances in mitochondrial sciences, cell metabolism, exercise physiology and nutrition are fueling innovation in nutrition-based therapies. Exerkine is seeking opportunities to expand its commercial operations, leverage its IP portfolio, and raise capital investment. Additionally, Exerkine provides R&D and consultation services to the nutritional and pharmaceutical industries. Contact us if you wish to learn more and how Exerkine can support your business. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/28b3b26b-4cb8-4c38-a7c7-a493359842bd

ALBANY, N.Y., Aug. 18, 2022 /PRNewswire/ -- YDS Pharmatech announced the publication of a paper revealing a novel human viral recognition mechanism in Nature Chemical Biology today. The publication was co-authored by Xing Che, Ph.D., founder and CEO of YDS Pharmatech, and by researchers at Tianjin Medical University led by Prof. Heng Zhang. The company helped reveal a new viral protein recognition mechanism, highlighting a promising new target for antiviral drugs. An important immune response factor, TRIM7, coordinates the attachment of ubiquitin to cellular proteins, tagging them for protein degradation. Recently, TRIM7 was also shown to have activity against human enterovirus, but the mechanism by which TRIM7 recognizes viral proteins remained unknown. In this study, YDS Pharmatech helped identify the specific molecular mechanism by which TRIM7 recognizes viral infection. A series of structural mutation studies performed by the Tianjin Medical University researchers indicated that the glutamine amino acid at the end of the viral protein drives recognition by TRIM7. YDS's protein dynamics simulations further consolidate the conclusion. Their atomic-level simulations showed how a subtle single mutation disrupts the interactions between the viral peptide and TRIM7, disrupting the protein's antiviral role. Moreover, these findings helped point to additional viral proteins that are recognized by TRIM7, including norovirus and SARS-CoV-2 proteins. Founder and CEO at YDS Pharmatech, Xing Che, Ph.D., says of this recent work, "We are glad YDS Pharmatech was able to contribute to this innovative research that will help to advance the E3 ligase, TRIM7, as a novel drug target for developing antiviral agents against several viruses, including SARS-CoV-2, the virus that causes COVID-19, and for developing new targeted protein degradation therapeutics." "New, more effective drugs are needed to address human health challenges," said James Kuo, MD, MBA, former CEO and co-founder of TRYP Therapeutics and advisor to YDS Pharmatech. "YDS Pharmatech uses innovative computational approaches to solve complex problems in biology. This is a great example of how this company brings value to drug discovery and scientific research." To learn more, read the full paper here: About YDS Pharmatech YDS Pharmatech is a privately held drug design company located in Albany, NY. The company has developed a proprietary drug design engine known as MERES™ (Modify-Evaluate-Reinforce-Evolve-Sampling). By leveraging a novel AI and biophysics computational platform, MERES™ shifts drug discovery away from random screening and towards an efficient, directed exploration of the chemical space. The company is also expanding its business to enzyme design by using AI to guide the exploration of protein sequence space towards stronger catalytic power. For more information, please visit yds-pharmatech.com. Follow us on LinkedIn. About MERES YDS Pharmatech's proprietary structure-based drug design engine, MERES (Modify-Evaluate-Reinforce-Evolve-Sampling), leverages evolutionary AI, computational biophysics, and statistical mechanics to optimize drug candidate molecular structure and improve binding affinities to targets. MERES requires only one molecule as input to create molecules with new IP values and the specified desired properties. MERES has already been used to accelerate biotech pipelines, has increased PROTAC candidate binding by 100-fold, discovered the world's first alphavirus inhibitor, and generated new IP for an allosteric kinase inhibitor. Contact YDS Pharmatech Name: Xing Che Email: [email protected] SOURCE YDS Pharmatech